In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


From Newton to Heisenberg--The New Physics of the Drug Industry

Executive Summary

While the current wave of high profile drug industry deals recalls the heady days of 1980s consolidation, the motivations are quite different. Managed care is forcing companies to prize the efficient leveraging of assets, not critical mass. In today's drug industry, companies will manage for strategic diversity, juggling a number of different platforms at one time. Successful companies will by no means all have been successful using the same set of tools.

You may also be interested in...

Waking the Giant: Business Model Innovation in the Drug Industry

The drug industry has reached the limits of its traditional business model, having collectively destroyed shareholder value since 2000. Companies' responses -- cost reductions, portfolio rationalization, productivity enhancements, bigger dealmaking -- are too little, too late. It's not enough to do business more efficiently; the industry needs to adopt new business models. Problem is: it's almost unprecedented to change models in the drug industry, though companies in other industries have done it under similarly challenging circumstances. Now it's time for Pharma to get moving. Since no company has yet taken a convincing stance on business model innovation, there's significant opportunity for one or more players to take the lead and create strategic advantage in doing so.

Reinventing Pharmacy: The Price Increase for Caremark Could Be a Price Decrease for Manufacturers

The battle between CVS and Express Scripts for ownership of Caremark has made little impact on drug-company executives. But there is an important implication for pricing in the Medicare Part D world: CVS wants to use Caremark to help it get higher payments for providing pharmacy services. But in the zero-sum game of reimbursement, any additional profits for chains will likely come from reduced prices on drugs.

Lilly’s ‘High Quality’ Donanemab Data Supports Unrestricted Medicare Coverage, Firm Says

As FDA decision on Alzheimer’s product approaches, new paper outlines Lilly’s arguments for unfettered Medicare coverage for donanemab once it is approved.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts